RYTM vs. MRUS, CORT, ARVN, INDV, JANX, TGTX, SMMT, DYN, VERA, and RCKT
Should you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Merus (MRUS), Corcept Therapeutics (CORT), Arvinas (ARVN), Indivior (INDV), Janux Therapeutics (JANX), TG Therapeutics (TGTX), Summit Therapeutics (SMMT), Dyne Therapeutics (DYN), Vera Therapeutics (VERA), and Rocket Pharmaceuticals (RCKT). These companies are all part of the "pharmaceutical preparations" industry.
Merus (NASDAQ:MRUS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings.
Merus presently has a consensus target price of $56.33, suggesting a potential upside of 16.49%. Rhythm Pharmaceuticals has a consensus target price of $47.20, suggesting a potential upside of 7.86%. Given Rhythm Pharmaceuticals' higher probable upside, research analysts plainly believe Merus is more favorable than Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals has a net margin of -238.50% compared to Rhythm Pharmaceuticals' net margin of -352.56%. Rhythm Pharmaceuticals' return on equity of -50.61% beat Merus' return on equity.
Merus has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Merus is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Merus. MarketBeat recorded 9 mentions for Rhythm Pharmaceuticals and 4 mentions for Merus. Merus' average media sentiment score of -0.03 beat Rhythm Pharmaceuticals' score of -0.49 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.
Merus has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500.
96.1% of Merus shares are held by institutional investors. 4.6% of Merus shares are held by company insiders. Comparatively, 4.7% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Merus received 49 more outperform votes than Rhythm Pharmaceuticals when rated by MarketBeat users. However, 65.87% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.52% of users gave Merus an outperform vote.
Summary
Merus beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Rhythm Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rhythm Pharmaceuticals Competitors List
Related Companies and Tools
